Choong Ang Vaccine Laboratory KRX:072020KOSDAQ
중앙백신 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked0since Sep 11
In Q2 2026, Choong Ang Vaccine Laboratory reported revenue of ₩11.9bn, down 1.2% year on year, and operating profit of ₩1.1bn. Choong Ang Vaccine Laboratory (중앙백신) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Choong Ang Vaccine Laboratory quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩11.9bn | -1.2% | ₩1.1bn margin 9.6% | ₩1.3bn |
| Q1 2026 | ₩12.6bn | -4.9% | ₩3.0bn margin 23.8% | ₩3.3bn |
| Q4 2025 derived | ₩12.8bn | +14.0% | ₩1.1bn margin 8.9% | ₩1.7bn |
| Q3 2025 | ₩11.0bn | +2.4% | ₩1.5bn margin 14.1% | ₩1.7bn |
| Q2 2025 | ₩12.0bn | -2.0% | ₩1.5bn margin 12.5% | ₩677m |
| Q1 2025 | ₩13.2bn | +16.8% | ₩2.3bn margin 17.3% | ₩2.1bn |
| Q4 2024 derived | ₩11.2bn | -8.8% | ₩581m margin 5.2% | ₩2.2bn |
| Q3 2024 | ₩10.7bn | +15.1% | ₩1.7bn margin 16.0% | ₩933m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Choong Ang Vaccine Laboratory top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Choong Ang Vaccine Laboratory news Korean headlines
No articles yet.